Fu Hong Han Lin (02696.HK) announced that the company's recombinant anti-PD-1 personalized monoclonal antibody injection (HLX10) combined with recombinant anti-EGFR humanized monoclonal antibody injection (HLX07) for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) completed the first patient administration in China.

HLX10 is an innovative biopharmaceutical developed independently by the company for the treatment of solid tumors. Currently, the possibility of its use in the treatment of chronic hepatitis B is being further explored. HLX07 is an improved innovative biomedical targeting EGFR developed independently by the company. It is expected to be used for treatment of various solid tumors such as colorectal cancer and nasopharyngeal cancer.

The main purpose of the trial was to evaluate the objective remission rate and safety of HLX10 and HLX07 in combination treatment for advanced head and neck squamous cell carcinoma at week 16. The second aim was to evaluate other efficacy endpoints, immunogenicity, and pharmacokinetic characteristics. Exploratory purposes include monitoring biomarkers of treatment response or drug resistance. (jc/a) (Quotation delayed at least 15 minutes. (The short selling information is as of 2020-07-29 16:25.)